Zvia Agur
Professor Zvia Agur is an eminent international biomathematician, who has made major contributions to the theory of disease dynamics, chemotherapy and vaccination policies optimization. Prof. Agur is founder of the Institute for Medical BioMathematics (IMBM), has been the president of the Israeli Society of Theoretical and Mathematical Biology, a member of the Board of Directors of the European Society of Mathematical and Theoretical Biology, and an editor of several professional publications. Her innovative research work has won national awards, has been published in a long line of leading scientific journals and is recognized by the academic community worldwide. Prof. Agur holds a Ph.D. from the Hebrew University in Jerusalem and the Université Libre in Brussels.
Education and Positions:
1971 B.Sc, Genetics and Microbiology, from the Hebrew University 1973  M.Sc., Genetics from the Hebrew University 1974 M,Sc studies in Philosophy of Science from the Hebrew University 1982  Ph.D., Biomathematics, Université Libre, Belgium 19871994  Senior Scientist, Weizmann Institute of Science, Rehovot, Israel 19941999  Associate Professor, Cell Research and Immunology, TelAviv University, Israel 1999  President, Institute for Medical Biomathematics (IMBM) 2000  Chairperson & CSO, Optimata Ltd.
Visiting Scientist:
1985 University of New York at Stoney Brook, USA
1989  Rockefeller University, New York, USA
1989  Ecole Normale Superieure, Paris;
1991  Imperial College of Science, UK;
1992  1994  Oxford University, UK.
Activity On Professional Societies:
1986 Member of the Society of Mathematical Biology (SMB) 1991 Member of the European Society of Mathematics in Biology and Medicine (ESMTB) 19961998  Acting President of the Israeli Society of Theoretical and Mathematical Biology (ISMTB) 1997 2003  Board of Directors of the European Society of Mathematical and Theoretical Biology (ESMTB) 19982001  President of the Israeli Society of Theoretical and Mathematical Biology. (ISMTB)
Academic and professional awards:
1974  Aharon Katzir Prize for Scientific Writing, Israel Academy of Science, Israel 1987  The Elaine Blond Career Development Chair, The Weizmann Institute of Science, Rehovot, Israel 1989  The Juludan Prize for Outstanding Scientific Achievements, Technion Israel Institute of Technology, Haifa 1987  JakubskindCymerman Research Prize, The Weizmann Institute of Science, Rehovot, Israel 2004  Best Paper Award, 6th International Conference on Cellular Automata for Research and Industry, ACRI. 2015  finalist for EU Prize for Women Innovators, European Commission.
Editorial Boards:
1996Associate Editor Jour. of Biological Systems / World Scientific Singapore. New Jersey. London. Hong Kong.
19971998Guest Associate Editor  Jour. Mathematical Bioscience / Elsevier.
1998Associate Editor  Book Series in Mathematical and Computational Biology. Wiley, UK
20002008Associate EditorJournal of M3AS, Mathematical Methods and Models in the Applied Sciences / World Scientific Singapore. New Jersey. London. Hong Kong.
2006Mathematical Modelling of Natural Phenomena  Editorial Board Member on Hematopoiesis and blood diseases
2010Computational and Mathematical Methods in Medicine  Editorial Board Member
2012Current Angiogenesis  Editorial Board Member
Recent selected publications:
Agur Z, HaleviTobias K, Kogan Y & Shlagman O. Employing dynamical computational models for personalizing cancer immunotherapy. Expert Opin Biol Ther., 26, 2016, pp 113.
Elishmereni M, Kheifetz Y, Shukrun I, Bevan GH, Nandy D, McKenzie KM, Kohli M, Agur Z. Prediction of individual response to androgen deprivation therapy in hormone sensitive prostate cancer stage patients by integrating a mathematical mechanistic model of tumor progression with clinical patient characteristics. Prostate, 76(1), 2016, pp 4857.
Kheifetz Y, Elishmereni M and Agur. Complex pattern of Interleukin11induced inflammation revealed by mathematical modeling of CReactive Protein dynamics. J Pharmacokinet Pharmacodyn., 41(5), 2014, pp 47991.
Agur Z, Elishmereni M & Kheifetz Y. Personalizing oncology treatments in solid cancer diseases by predicting drug efficacy, sideeffects, and improved therapy: mathematics, statistics and their integration. Syst Biol Med., 6(3), 2014, pp 23953.
Agur Z. The resonance phenomenon in population persistence: Can the same theory guide both national security policies and personalized medicine? Croat Med J., 55(2), 2014, pp 93102.
Kogan Y, Agur Z, Elishmereni M. A mathematical model for the immunotherapeutic control of the Th1/Th2 imbalance in melanoma. Discrete and Continuous Dynamics  Series B., 18(4), 2013, pp 10171030.
Kogan Y, HaleviTobias K, Elishmereni M, Vuk Pavlovic, S, Agur Z. Reconsidering the Paradigm of Cancer Immunotherapy by Computationally Aided RealTime Personalization. Cancer Res., 72(9), 2012, pp 22182227.
Agur, Z. and Vuk Pavlovic, S. Mathematical Modeling in Immunotherapy of Cancer: Personalizing Clinical Trials. Molecular Therapy, 20(1), 2012: 12.
Vainstein, V., Kirnasovsky, O. U., Kogan, Y., Agur, Z. Strategies for cancer stem cell elimination: Insights from mathematical modeling, in press.
Hochman, G. and Agur, Z. Deciphering fate decision in normal and cancer stem cells  Mathematical models and their experimental verification. In Mathematical Methods and Models in Biomedicine, Ledjewicz, Schaettler, Friedman, eds, 2012.
Agur, Z., Kirnasovsky, O.U., Tencer, L., Wasserman, G., Harrison, H., Lamb, R. and Clarke, R.B. Use of Dickkopf1 protein for diverting proliferating breast cancer stem cells to differentiation, as predicted mathematically and validated in vitro. PLoS one 2011 6(9) e24225.
Jager, E., van der Velden, V., te Marvelde, J., Roland, G., Walter, B., Agur, Z., Vainstein, V. Targeted drug delivery by gemtuzumab ozogamicin: mechanismbased pharmacokinetic model for treatment strategy improvement and prediction of individual responses. PloS one September 2011, 6(9), e24265.
Elishmereni, M., Kheifetz, Y., Søndergaard, H., Overgaard, R.V., Agur, Z. An Integrated Disease/Pharmacokinetic/Pharmacodynamic Model Suggests Improved Interleukin21 Regimens Validated Prospectively for Mouse Solid Cancers. PLoS Comput Biol. 2011 Sep;7(9):e1002206. Epub 2011 Sep 29.
Kronik N., Kogan Y., Elishmereni M., HaleviTobias K., Vuk Pavlović S., Agur Z. Predicting Effect of Prostate Cancer Immunotherapy by Personalized Mathematical Models. PLoS one, 2011; 6(9):e24225. Epub 2011 Sep 6.
Agur,Z. From the Evolution of Toxin Resistance to Virtual Clinical Trials the Role of Mathematical Models in Oncology, Future Oncol. 2010 Jun; 6(6):91727.
Kogan Y., Forys U., Shukron O., Kronik N., Agur Z. Cellular immunotherapy for high grade Gliomas: mathematical analysis deriving efficacious infusion rates based on patient requirements. SIAM J. Appl. Math. 70(6), 2010, pp. 19531976
Agur, Z., Kogan, Y., Levi, L., Harrison, H., Lamb, R., Kirnasovsky, O. U., Clarke, R. B. Disruption of a quorum sensing mechanism may trigger somatic evolution of cancer: a simple discrete model and its preliminary in vitro verification in mammary cancer stem cells. Biol Direct 2010, 5:20.
Agur, Z. Bloch, N., Gorelik, B., Kleiman, M., Kogan Y., Sagi, Y., Sidransky, D., Ronen, Y. Developing oncology drugs using virtual patients of vascular tumor diseases. In "Systems biology in Drug Discovery and Development"; Ed. Daniel L. Young and Seth Michelson; Series: Technologies for the Pharmaceutical Industry; Series Editor: Dr. Sean Ekins; John Wiley & Sons, 2009.
Gorelik, B., Ziv, I., Shohat, R., Wick, M., Webb, C., Hankins, D., Sidransky, D., Agur, Z. Efficacy of once weekly docetaxel combined with bevacizumab for patients with intense angiogenesis: validation of a new theranostic method in mesenchymal chondrosarcoma xenografs. Cancer Research, 68: (21) November, 1 2008, PP. 903340.
Kirnasovsky, O.U., Kogan, Y, Agur, Z. Analysis of a mathematical model for the molecular mechanism of mammary stem cell fate decision. Mathematical Modelling of Natural Phenomena Vol 3 (7) 2008 pp. 78  89.
Kirnasovsky, O.U., Kogan, Y, Agur, Z. Resilience in developing tissues: development of the Agur Daniel Ginossar model. Disc. Cont. Dyn. Sys. Volume 10, 2008, Pages: 129 148.
Zvia A., Elishmereni, M., Kogan, Y., Kheiffetz, Y., Ziv, I., Shoham, M. and Vainstein, V. Mathematical modeling as a new approach for improving the efficacy/toxicity profile of drugs: the thrombocytopenia case study. In Preclinical Development Handbook, Shayne Gad Ed., John Wiley and Sons, USA. 2008, pp 12291266.
Kronik, N., Yui Kogan, Y., Vainstein, V., Agur, Z. Improving alloreactive ctl immunotherapy for malignant gliomas using a simulation model of their interactive dynamics. Cancer Immunol Immunother. Mar;57(3):425439 (2008). Epub 2007 Sep 7.
Cappuccio, A, Elishmereni, M, and Agur, Z. Optimization of Interleukin21 Immunotherapeutic Strategies. J Theor Biol. 2007 Sep 21; 248(2):25966. Epub 2007 May 18.
Cappucio, A, Elishmereni, M, Agu,r Z. Cancer immunotherapy by interleukin21: potential treatment strategies evaluated in a mathematical model. Cancer Research, 66 (14), 2006 ( 7293  300).
Agur, Z., Biomathematics in the development of personalized medicine in oncology. Future Oncol., 2 (1) 2006 (pp. 3942).
Agur, Z., Hassin R., Levy S. Optimizing chemotherapy scheduling using local search heuristics, Operations Research.; 54 (5), 2006 (pp.829846).
Kheifetz, Y., Kogan Y. and Agur, Z. Longrange predictability in models of cell populations subjected to phasespecific drugs: Growthrate approximation using properties of positive compact operators. Mathematical Models & Methods in the Applied Sciences. 16 (7), 2006, (pp. 118).
Presnov, E.V. nd Agur, Z. The role of timedelays, slow processes and chaos in modulating the cell cycle clock . Mathematical Biosc & Engin, 2(3), 2005 (pp.625642).
Vainstein, V., Ginosar, Y., Shoham, M., Ranmar, D., Ianovski, A., Agur, Z. The complex effect of granulocyte on human granulopoiesis analyzed by a new physiologicallybased mathematical model. Jour Theor Biol. 234(3), 2005 (pp.31127).
Ribba, B., Marron, K., Alarcon, T., Maini, P., Agur, Z. A mathematical model of doxorubicin treatment efficacy for nonHodgkins lymphoma: Investigation of the current protocol through theoretical modelling results Bull. Math. Biol., 67, 2005 (pp. 7999).
Arakelyan, L,, Merbl, Y., Agur, Z. Vessel maturation effects on tumour growth: validation of a computer model in implanted human ovarian carcinoma spheroids Eur. Jour. Cancer, 41, 2005 (pp.159167).
Agur, Z., Arakelyan, L., Daugulis, P., Ginosar, Y. Hopf point analysis for angiogenesis models. Discrete and Continuous Dynamical Systems Series B, 4 (1), 2004 (pp. 2938).
Skomorovski, K., Harpak, H., Ianovski, A., Vardi, M., Visser, TP., Hartong, S., Van Vliet, H., Wagemaker, G., Agur, Z. New TPO treatment schedules of increased safety and efficacy: pre clinical validation of a thrombopoiesis simulation model. Br. Jour. Haematol, 123 (4), 2003 (pp. 683691).
Arakelyan, L., Vainstain, V., Agur, Z. A computer algorithm describing angiogenesis and vessel maturation and its use for studying the effects of antiangiogenic and antimaturation therapy on vascular tumor growth, Angiogenesis, 5 (3), 2002 (pp. 20314).
Agur Z., Daniel Y., Ginosar Y. The universal properties of stem cells as pinpointed by a simple discrete model. Jour. Math. Biol., 44 (1), 2002 (pp.7986).
